BRIEF published on 04/08/2026 at 22:05, 7 days 9 hours ago Inventiva Submits 2025 Financial Reports to AMF and SEC Inventiva 2025 Financial Reports MASH Treatments Biopharmaceutical Developments AMF And SEC Filings
BRIEF published on 04/08/2026 at 22:05, 7 days 9 hours ago Inventiva files its Universal Registration Document and its 2025 Annual Report Annual Report Biopharmaceutical Registration Document Inventiva MASH
PRESS RELEASE published on 04/08/2026 at 22:00, 7 days 10 hours ago Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F Inventiva files 2025 Universal Registration Document and Annual Report on Form 20-F with AMF and SEC, focusing on MASH therapies Biopharmaceutical 2025 Filing Inventiva MASH
BRIEF published on 04/02/2026 at 15:55, 13 days 16 hours ago JP Morgan Chase & Co. crosses the thresholds for participation in INVENTIVA Voting Rights Threshold Crossing JP Morgan Inventiva Equity Swap
BRIEF published on 03/30/2026 at 22:16, 16 days 9 hours ago Inventiva Announces 2025 Financial Results and Business Update Public Offering Cash Reserves Inventiva Lanifibranor 2025 Financial Results
PRESS RELEASE published on 03/30/2026 at 22:11, 16 days 9 hours ago Inventiva reports 2025 full year results and provides a business update Inventiva reports 2025 full year results with €4.5 million revenues, provides business update on strategic pipeline, clinical trials, and financial performance Financial Performance Business Update Clinical Trials Inventiva 2025 Results
BRIEF published on 03/23/2026 at 22:05, 23 days 9 hours ago Inventiva announces its 2025 annual financial results Financial Results Conference Call Investors Steatohepatitis Oral Therapy
BRIEF published on 03/23/2026 at 22:05, 23 days 9 hours ago Inventiva Announces Schedule for 2025 Financial Results Financial Results Conference Call Biopharmaceutical Inventiva MASH
PRESS RELEASE published on 03/23/2026 at 22:00, 23 days 10 hours ago Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results Inventiva to release 2025 full-year financial results on March 30, 2026, followed by a conference call on March 31, 2026. Details on the company's website Financial Results Conference Call Biopharmaceutical Inventiva Therapy
BRIEF published on 03/23/2026 at 09:51, 23 days 22 hours ago JP Morgan Chase & Co. crosses ownership thresholds in INVENTIVA Actions Participation Threshold Crossing JP Morgan Inventiva
Published on 04/16/2026 at 01:50, 6 hours 10 minutes ago Challenger DFS Pit Optimisation Drilling Complete
Published on 04/15/2026 at 23:00, 9 hours ago EV Nickel Intersects 1.20% Nickel Over 9.80 Metres at Langmuir South
Published on 04/15/2026 at 22:30, 9 hours 30 minutes ago Avant Brands Announces its Annual General and Special Meeting
Published on 04/15/2026 at 22:15, 9 hours 45 minutes ago APPULSE CORPORATION (Listed on the TSX Venture Exchange - Symbol 'APL') - Reporting Results for the 2025 Fiscal Year and Adoption of Semi-annual Reporting
Published on 04/15/2026 at 22:00, 10 hours ago NioCorp to Participate in Maxim Group's "Mining the Industrial Supply Chain" Conference on Apr. 21
Published on 04/16/2026 at 07:45, 15 minutes ago Voltatron Achieves Significantly Improved Profitability and a Strengthened Capital Structure in Fiscal Year 2025 – Further Growth Spurt and Increase in Earnings Expected
Published on 04/16/2026 at 07:30, 30 minutes ago Weak demand reflected in R. STAHL’s 2025 figures – Executive Board expects business to stabilize at a modest level in 2026
Published on 04/16/2026 at 07:00, 1 hour ago NFON confirms preliminary results for 2025 – profitability improves, AI solutions drive business growth
Published on 04/16/2026 at 07:00, 1 hour ago FUCHS presents its new strategy – “FOCUS TO WIN” on the path to its 100th anniversary
Published on 04/16/2026 at 07:00, 1 hour ago BioVersys announces first patient first visit in HABP/VABP pivotal Phase 3 RIV-TARGET trial of BV100
Published on 04/15/2026 at 20:12, 11 hours 48 minutes ago Covivio - Q1 2026 activity : Strategic progress driving growth
Published on 04/15/2026 at 17:45, 14 hours 15 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of March 31, 2026
Published on 04/15/2026 at 07:30, 1 day ago Covivio Hotels - Revenues at end-March 2026 : +1.4% Revenue growth year-on-year
Published on 04/15/2026 at 07:30, 1 day ago Covivio is accelerating its expansion in the hotel sector with the acquisition of four hotels in Milan for €217 million
